-
1
-
-
0142121292
-
Treatment of locally advanced pancreatic cancer in the real world: Population-based practices and effectiveness
-
Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003;21(18):3409-3414.
-
(2003)
J Clin Oncol
, vol.21
, Issue.18
, pp. 3409-3414
-
-
Krzyzanowska, M.K.1
Weeks, J.C.2
Earle, C.C.3
-
2
-
-
65549143674
-
Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: A qualitative systematic review
-
Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009;27(13):2269-2277.
-
(2009)
J Clin Oncol
, vol.27
, Issue.13
, pp. 2269-2277
-
-
Huguet, F.1
Girard, N.2
Guerche, C.S.3
-
3
-
-
77954771890
-
5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O] versus gemcitabine [G] as first-line treatment for meta- static pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial
-
abstract 4010
-
Conroy T, Desseigne M, Ychou M, et al. Randomized Phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O] versus gemcitabine [G] as first-line treatment for meta- static pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol. 2010; 28(Suppl, abstract 4010):S15.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Conroy, T.1
Desseigne, M.2
Ychou, M.3
-
4
-
-
0035501222
-
Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma
-
Bo G, De Paoli A, Innocente R, et al. Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2001;51:736-740.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.51
, pp. 736-740
-
-
Bo, G.1
de Paoli, A.2
Innocente, R.3
-
5
-
-
70249130566
-
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411
-
Crane CH, Winter K, Regine W, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol. 2009;27: 4096-4102.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4096-4102
-
-
Crane, C.H.1
Winter, K.2
Regine, W.3
-
6
-
-
0036643954
-
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies
-
Vaishampayan UN, Ben-Josef E, Philip PA, et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys. 2002;53: 675-679.
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.53
, pp. 675-679
-
-
Vaishampayan, U.N.1
Ben-Josef, E.2
Philip, P.A.3
-
7
-
-
0027160447
-
Investigation of taxol as a potential radiation sensitizer
-
Choy H, Rodriguez F F, Koester S, et al. Investigation of taxol as a potential radiation sensitizer. Cancer. 1993;71:3774-3778.
-
(1993)
Cancer
, vol.71
, pp. 3774-3778
-
-
Choy, H.1
Rodriguez, F.F.2
Koester, S.3
-
8
-
-
0035312196
-
Paclitaxel and concurrent radiation for locally advanced pancreatic cancer
-
Safran H, Moore T, Iannitti D, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2001;49:1275-1279.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.49
, pp. 1275-1279
-
-
Safran, H.1
Moore, T.2
Iannitti, D.3
-
9
-
-
0031044606
-
Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A Phase I study
-
Safran H, King T P, Choy H, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a Phase I study. J Clin Oncol. 1997;15:901-907.
-
(1997)
J Clin Oncol
, vol.15
, pp. 901-907
-
-
Safran, H.1
King, T.P.2
Choy, H.3
-
10
-
-
0842327290
-
A Phase II study of external beam irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: RTOG 98-12
-
Rich TA, Harris J, Abrams R, et al. A Phase II study of external beam irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: RTOG 98-12. Am J Clin Oncol. 2007;27(1): 51-56.
-
(2007)
Am J Clin Oncol
, vol.27
, Issue.1
, pp. 51-56
-
-
Rich, T.A.1
Harris, J.2
Abrams, R.3
-
11
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris, H.A.1
Moore, M.J.2
Andersen, J.3
-
12
-
-
0035577889
-
Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer
-
Blackstock AW, Lesser GJ, Fletcher-Steede J, et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:1281-1289.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.51
, pp. 1281-1289
-
-
Blackstock, A.W.1
Lesser, G.J.2
Fletcher-Steede, J.3
-
13
-
-
0000643645
-
A Phase I study of preoperative gemcitabine (GEM) with radiation therapy (RT) followed by postoperative GEM for patients with localized, resectable pancreatic adenocarcinoma (PAC)
-
Hoffman J P, McGinn CJ, Szarka C, et al. A Phase I study of preoperative gemcitabine (GEM) with radiation therapy (RT) followed by postoperative GEM for patients with localized, resectable pancreatic adenocarcinoma (PAC). Proc Am Soc Clin Oncol. 2007;18:283a.
-
(2007)
Proc Am Soc Clin Oncol
, vol.18
-
-
Hoffman, J.P.1
McGinn, C.J.2
Szarka, C.3
-
14
-
-
0036719234
-
Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: A Phase I trial
-
Safran H, Dipetrillo T, Iannitti D, et al. Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial. Int J Radiat Oncol Biol Phys. 2002;54:137-141.
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.54
, pp. 137-141
-
-
Safran, H.1
Dipetrillo, T.2
Iannitti, D.3
-
15
-
-
43249110658
-
Determinants of RASistance to anti-epidermal growth factor receptor agents
-
Baselga J, Rosen N. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol. 2008;26:1582-1584.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1582-1584
-
-
Baselga, J.1
Rosen, N.2
-
16
-
-
0032704708
-
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
-
Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3631-3652
-
-
Rowinsky, E.K.1
Windle, J.J.2
Von Hoff, D.D.3
-
17
-
-
0024202761
-
Sample size considerations for studies comparing survival curves using historical controls
-
Dixon DO, Simon R. Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol. 1988;41:1209-1213.
-
(1988)
J Clin Epidemiol
, vol.41
, pp. 1209-1213
-
-
Dixon, D.O.1
Simon, R.2
-
18
-
-
33845382806
-
Non-parametric estimation from incomplete observation
-
Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat. 2007;53:457-481.
-
(2007)
J Am Stat
, vol.53
, pp. 457-481
-
-
Kaplan, E.L.1
Meier, P.2
-
19
-
-
0000336139
-
Regression models and life tables
-
Cox DR. Regression models and life tables. J R Stat Soc. 2007;34: 187-229.
-
(2007)
J R Stat Soc
, vol.34
, pp. 187-229
-
-
Cox, D.R.1
-
20
-
-
0037783798
-
Clinical research in pancreatic cancer: The Radiation Therapy Oncology Group trials
-
Willett CG, Safran H, Abrams RA, et al. Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys. 2003;56:31-37.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.56
, pp. 31-37
-
-
Willett, C.G.1
Safran, H.2
Abrams, R.A.3
-
21
-
-
0030748489
-
Enhanced radioresponse of paclitaxel sensitive and -resistant tumours in vivo
-
Milross CG, Mason KA, Hunter NR, et al. Enhanced radioresponse of paclitaxel sensitive and -resistant tumours in vivo. Eur J Cancer. 1997;33:1299-1308.
-
(1997)
Eur J Cancer
, vol.33
, pp. 1299-1308
-
-
Milross, C.G.1
Mason, K.A.2
Hunter, N.R.3
-
22
-
-
0029113685
-
Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa
-
Mason KA, Milas L, Peters LJ. Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa. Int J Radiat Oncol Biol Phys. 1995;32:1381-1389.
-
(1995)
Int J Radiat Oncol Biol Phys
, vol.32
, pp. 1381-1389
-
-
Mason, K.A.1
Milas, L.2
Peters, L.J.3
-
23
-
-
9544220646
-
p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma
-
Safran H, King T, Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer. 1996;78:1203-1210.
-
(1996)
Cancer
, vol.78
, pp. 1203-1210
-
-
Safran, H.1
King, T.2
Choy, H.3
Et al.4
-
24
-
-
0002291979
-
Gemcitabine as a radiation sensitizer
-
Lawrence T. Gemcitabine as a radiation sensitizer. Semin Oncol. 2007;22:68-71.
-
(2007)
Semin Oncol
, vol.22
, pp. 68-71
-
-
Lawrence, T.1
-
25
-
-
4644239753
-
Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
-
Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003;34:107-116.
-
(2003)
Int J Gastrointest Cancer
, vol.34
, pp. 107-116
-
-
Blackstock, A.W.1
Tepper, J.E.2
Niedwiecki, D.3
-
26
-
-
0035890443
-
Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer
-
McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202-4208.
-
(2001)
J Clin Oncol
, vol.19
, pp. 4202-4208
-
-
McGinn, C.J.1
Zalupski, M.M.2
Shureiqi, I.3
-
27
-
-
0028603395
-
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
-
Kohl NE, Wilson FR, Mosser SD, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A. 1994;91:9141-9145.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 9141-9145
-
-
Kohl, N.E.1
Wilson, F.R.2
Mosser, S.D.3
-
28
-
-
23844517889
-
A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study
-
Macdonald JS, McCoy S, Whitehead R P, et al. A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs. 2005;23:485-487.
-
(2005)
Invest New Drugs
, vol.23
, pp. 485-487
-
-
Macdonald, J.S.1
McCoy, S.2
Whitehead, R.P.3
-
30
-
-
2342645506
-
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
-
Van Cutsem E, de Belde H V, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1430-1438
-
-
van Cutsem, E.1
de Belde, H.V.2
Karasek, P.3
|